Nasdaq · Healthcare
DEXCOM INC (DXCM)
As-reported financials and recent SEC filings for DEXCOM INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$4.66B
Net income
$836.3M
Net margin
17.9%
Diluted EPS
$2.09
ROE
30.5%
P/E (TTM)
32.3×
Market cap
$29.08B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.66B | $4.03B | $3.62B | $2.91B | $2.45B |
| Gross profit | $2.80B | $2.44B | $2.29B | $1.88B | $1.68B |
| Operating income | $911.8M | $600.0M | $597.7M | $391.2M | $265.8M |
| Net income | $836.3M | $576.2M | $541.5M | $341.2M | $216.9M |
| Diluted EPS | $2.09 | $1.42 | $1.30 | $0.82 | $0.53 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-05
View on EDGAR →1442026-06-04
View on EDGAR →1442026-06-03
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →Go deeper on DXCM
Search DEXCOM INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.